Related Experiment Video
Updated: May 24, 2026
07:58
Establishment of a Surgically-induced Model in Mice to Investigate the Protective Role of Progranulin in Osteoarthritis
Published on: February 25, 2014
Progranulin: an emerging target for FTLD therapies
Jennifer Gass1, Mercedes Prudencio, Caroline Stetler
1Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA.
Brain Research
|February 18, 2012
Summary
Mutations in the progranulin gene (GRN) cause frontotemporal lobar degeneration (FTLD) by reducing PGRN protein levels. Therapies aim to increase PGRN to treat this dementia.
Area of Science:
- Neuroscience
- Genetics
- Biochemistry
Background:
- Frontotemporal lobar degeneration (FTLD) is a common dementia linked to frontal and temporal lobe neurodegeneration.
- Approximately 10-40% of FTLD cases are inherited, with mutations in the progranulin gene (GRN) being a significant cause.
- GRN mutations lead to deficiencies in progranulin (PGRN) protein, essential for cellular functions.
Purpose of the Study:
- To review PGRN biology and its role in FTLD.
- To understand mechanisms regulating PGRN levels.
- To identify potential therapeutic strategies for increasing PGRN in FTLD patients.
Main Methods:
- Literature review of studies on PGRN biology and FTLD.
- Analysis of identified compounds, genetic factors, and PGRN receptors regulating PGRN levels.
- Examination of the consequences of abnormal PGRN levels.
Main Results:
- Over 70 GRN mutations are linked to FTLD by causing PGRN deficiency.
- Several modulators of PGRN levels have been identified.
- Maintaining appropriate PGRN levels is critical, as extremes can cause neurodegeneration or cancer.
Conclusions:
- Understanding PGRN regulation is key to developing FTLD therapies.
- Targeting PGRN levels offers a promising therapeutic avenue for inherited FTLD.
- Further research is needed to develop safe and effective PGRN modulators.
More Related Videos
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...